Company Registry

Iaterion Inc
Profile last edited on: 6/24/22

Next generation, life-supporting medicines
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6085 Grizzly Peak Boulevard
Oakland, CA 94611
   (510) 350-7870
Multiple Locations:   
Congressional District:   13
County:   Alameda

Public Profile

Iaterion Inc biotechnology company defining itself as designing innovative and novel therapeutics to improve overall health and wellness. eecent developments at Iaterion include cancer, immune modulation, antivirals and nuclear receptor modulation. Responding to the global call for COVID-19 pandemic solution - an urgent need for a safe and effective treatment to combat coronaviruses, prevent transmission via asymptomatic individuals, and to halt severe progression in early infected individuals - Iaterion management indicate the firm as having identified a combination of antiviral compounds and immune modulating compounds which suggest the opossbility of applicability not only to the current pandemic, but also to future, novel strains. Further, manageent suggest that Iaterion’s AVIM1 compound can halt the emergence of a future pandemic wave. Management indicate that early in the Covid outbreak, Iaterion had identified multiple antiviral compounds that neutralize SARS-CoV-2, SARS and MERS at very high potency and selectivity. Iaterion’s leads are 50-100 times more potent than Remdesivi

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Isaac Cohen -- CEO

  Klaus D Kohl -- CTO

  Dale C Leitman --

SBIR firms in the news

There are no news available.